AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
BrightSpring's Onco360 Selected as National Pharmacy Partner for New Cancer and Rare Disease Drugs
ByAinvest
Wednesday, Jun 18, 2025 4:31 pm ET1min read
BrightSpring Health Services, through its specialty pharmacy Onco360, has been selected as the national pharmacy partner for several newly approved therapies in the treatment of advanced cancers and rare genetic disorders. The therapies include GOMEKLI for neurofibromatosis type 1, AVMAPKI FAKZYNJA CO-PACK for recurrent low-grade serous ovarian cancer, and IBTROZI for ROS1-positive non-small cell lung cancer. Onco360 will provide access, education, data, and expert support for these innovative treatments.
BrightSpring Health Services, a leading provider of home- and community-based pharmacy and health solutions, has announced that its specialty pharmacy, Onco360, has been selected as the national pharmacy partner for several newly approved therapies in the treatment of advanced cancers and rare genetic disorders. The announcement was made on June 18, 2025, highlighting the company's commitment to expanding access to innovative treatments [1].Onco360 will provide access, education, data, and expert support for the following newly approved therapies:
- GOMEKLI™ for neurofibromatosis type 1 (NF1), a rare genetic disorder that affects the nervous system. The medication is approved for adult and pediatric patients 2 years of age and older with symptomatic plexiform neurofibromas (PN) not amenable to complete resection [1].
- AVMAPKI™ FAKZYNJA™ CO-PACK for recurrent low-grade serous ovarian cancer (LGSOC). This therapy is approved for adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy [1].
- IBTROZI™ for ROS1-positive non-small cell lung cancer (NSCLC). The medication is approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC [1].
BrightSpring President and CEO Jon Rousseau stated, "At Onco360, we continue to partner with innovators and manufacturers to deliver groundbreaking medicines and therapies to patients facing serious, life-threatening conditions, giving them additional hope" [1].
Onco360, a leading independent specialty pharmacy, dispenses nationally through its network of URAC- and ACHC-accredited Specialty Pharmacies. The company has been expanding its services and partnerships to provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients, and patients daily [1].
References:
[1] https://www.tradingview.com/news/reuters.com,2025-06-18:newsml_GNX8ZLsnr:0-brightspring-health-services-announces-onco360-selected-as-national-pharmacy-partner-for-multiple-new-cancer-and-rare-disease-drugs/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet